MDT

95.6

+0.46%↑

VEEV

290.6

+2.46%↑

A

145.15

+0.79%↑

HQY

95.89

+3.35%↑

TLRY

1.52

-5%↓

MDT

95.6

+0.46%↑

VEEV

290.6

+2.46%↑

A

145.15

+0.79%↑

HQY

95.89

+3.35%↑

TLRY

1.52

-5%↓

MDT

95.6

+0.46%↑

VEEV

290.6

+2.46%↑

A

145.15

+0.79%↑

HQY

95.89

+3.35%↑

TLRY

1.52

-5%↓

MDT

95.6

+0.46%↑

VEEV

290.6

+2.46%↑

A

145.15

+0.79%↑

HQY

95.89

+3.35%↑

TLRY

1.52

-5%↓

MDT

95.6

+0.46%↑

VEEV

290.6

+2.46%↑

A

145.15

+0.79%↑

HQY

95.89

+3.35%↑

TLRY

1.52

-5%↓

Search

Ocular Therapeutix Inc

Отворен

СекторЗдравеопазване

11.71 -1.84

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

11.6

Максимум

12.21

Ключови измерители

By Trading Economics

Приходи

-3.8M

-68M

Продажби

2.8M

13M

Марж на печалбата

-503.856

Служители

274

EBITDA

146K

-64M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+75.93% upside

Дивиденти

By Dow Jones

Следващи печалби

13.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

544M

2.5B

Предишно отваряне

13.55

Предишно затваряне

11.71

Настроения в новините

By Acuity

67%

33%

326 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Ocular Therapeutix Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.10.2025 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Takaichi's Policy Steps -- Market Talk

20.10.2025 г., 23:43 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

20.10.2025 г., 23:36 ч. UTC

Пазарно говорене

Gold Edges Higher on Likely Dip-Buying Interest -- Market Talk

20.10.2025 г., 22:14 ч. UTC

Пазарно говорене

Zions Management Confident $50M Charge Was Isolated Event -- Market Talk

20.10.2025 г., 22:00 ч. UTC

Печалби
Придобивния, сливания и поглъщания

Berkshire May Have Left $50 Billion on Table. Apple Stock Hit a Record. -- Barrons.com

20.10.2025 г., 21:49 ч. UTC

Придобивния, сливания и поглъщания

Kering Sells Beauty Business to L'Oréal. Everyone but This Company Wins. -- Barrons.com

20.10.2025 г., 20:56 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Moved the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

20.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

20.10.2025 г., 20:38 ч. UTC

Печалби

Steel Dynamics: Encouraging Demand Drivers of Manufacturing Onshoring, Infrastructure Program Funding, Lower Interest Rates, Increasing Regionalization of Supply Chains in U.S. >STLD

20.10.2025 г., 20:38 ч. UTC

Печалби

Steel Dynamics: Expect to Benefit From Stronger Demand Across Platforms, Including Aluminum Flat Rolled Products, as We Move Into 2026 >STLD

20.10.2025 г., 20:38 ч. UTC

Печалби

Steel Dynamics: Some Order Hesitancy From Flat Rolled Steel Customers Due to Domestic Trade Actions >STLD

20.10.2025 г., 20:36 ч. UTC

Печалби

Steel Dynamics: Continue to Observe Some Customer Inventory Overhang of Value-Added Flat Rolled Products That Were Imported Earlier This Yr >STLD

20.10.2025 г., 20:36 ч. UTC

Печалби

Steel Dynamics: View U.S. Intl Trade Commission's Final Determinations on Coated Flat Rolled Steel as a Significant Positive Development >STLD

20.10.2025 г., 20:36 ч. UTC

Печалби

Steel Dynamics: Discussions With Customers Reinforce the Increasing Importance of Low-Carbon, U.S.-Made Steel and Aluminum, Positioning Our Businesses for a Long-Term Competitive Advantage >STLD

20.10.2025 г., 20:36 ч. UTC

Печалби

Steel Dynamics: Improving Market Conditions, Including Increased Trade Stability and Favorable Interest Rate Environment, Will Contribute to Strong Domestic Demand for Steel and Aluminum >STLD

20.10.2025 г., 20:16 ч. UTC

Пазарно говорене

Canada Labor-Market Indicators Lean Dovish -- Market Talk

20.10.2025 г., 20:05 ч. UTC

Печалби

GE Aerospace Earnings Are on Tap. After the Turnaround, Investors Wonder What's Next. -- Barrons.com

20.10.2025 г., 19:39 ч. UTC

Печалби
Придобивния, сливания и поглъщания

Industrials Post Positive Earnings. 3 Stocks Whose Charts Say 'Buy.' -- Barrons.com

20.10.2025 г., 19:34 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Jump on Colder Weather Outlook -- Market Talk

20.10.2025 г., 19:32 ч. UTC

Пазарно говорене

Oil Futures Extend Losses on Oversupply Concerns -- Market Talk

20.10.2025 г., 19:00 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20.10.2025 г., 18:29 ч. UTC

Пазарно говорене

Apple Sitting on Best Long-Term Product Roadmap in Years -- Market Talk

20.10.2025 г., 18:11 ч. UTC

Пазарно говорене

Economic Vital Signs Missing in Bank of Canada Survey -- Market Talk

20.10.2025 г., 18:04 ч. UTC

Пазарно говорене

Uncertainty Remains Top Concern Among Canada Firms -- Market Talk

20.10.2025 г., 17:03 ч. UTC

Пазарно говорене

Weak Demand Signals Narrower Profit Margins For Canada Firms -- Market Talk

20.10.2025 г., 17:01 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

20.10.2025 г., 17:01 ч. UTC

Пазарно говорене

Bank of Canada Surveys Present Shaky Economic Outlook -- Market Talk

20.10.2025 г., 16:43 ч. UTC

Пазарно говорене

Canada Public-Sector Workers Fret Most On Labor-Market Weakness -- Market Talk

20.10.2025 г., 16:25 ч. UTC

Пазарно говорене

U.S. Natural Gas Extends Rebound on Weather Outlook -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Ocular Therapeutix Inc Прогноза

Ценова цел

By TipRanks

75.93% нагоре

12-месечна прогноза

Среден 20.83 USD  75.93%

Висок 31 USD

Нисък 14 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocular Therapeutix Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

13

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

6.97 / 7.62Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

326 / 371 Класиране в Здравеопазване

Настроения в новините

Мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
help-icon Live chat